论文部分内容阅读
目的探讨孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的临床疗效及安全性。方法选取江苏大学附属宜兴市人民医院儿科2014年1月—2016年1月收治的过敏性紫癜患儿80例,根据随机数字表法分为对照组和治疗组,各40例。对照组患儿给予常规治疗,治疗组患儿在对照组基础上给予孟鲁司特钠联合地氯雷他定治疗,比较两组患儿的临床疗效及皮疹、消化道症状、关节症状消失时间、住院时间,并观察患儿不良反应发生情况。结果治疗组患儿治疗总有效率高于对照组(P<0.05)。治疗组患儿皮疹、消化道症状、关节症状消失时间及住院时间短于对照组(P<0.05),两组患儿均未出现严重不良反应。结论采用孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的临床疗效确切,可有效改善患儿的临床症状,缩短住院时间,且安全性高。
Objective To investigate the clinical efficacy and safety of montelukast combined with desloratadine in the treatment of children with Henoch-Schonlein purpura. Methods 80 cases of children with Henoch-Schonlein purpura who were treated in Yixing Municipal People’s Hospital affiliated to Jiangsu University from January 2014 to January 2016 were divided into control group and treatment group according to the random number table method, 40 cases in each group. Children in the control group were given routine treatment. The children in the treatment group were treated with montelukast sodium and desloratadine on the basis of the control group. The clinical efficacy, rash, gastrointestinal symptoms, disappearance of joint symptoms , Hospital stay, and observed the incidence of adverse reactions in children. Results The total effective rate of treatment group was higher than that of control group (P <0.05). The skin rash, gastrointestinal symptoms, disappearance of joint symptoms and hospital stay in the treatment group were shorter than those in the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Montelukast combined with desloratadine treatment of children with anaphylactoid purpura clinical curative effect is exact, can effectively improve children’s clinical symptoms, shorten the hospital stay, and high safety.